Tirofiban, eptifibatide and abciximab in minimizing CK-MB release during coronary intervention (TEAM trial)

被引：0
|
作者：
Sharma, SK
Richard, M
Kini, AS
Suleman, J
Perez, N
King, T
Fisher, EA
Reich, D
Marmur, JD
机构：
[1] Mt Sinai Hosp, New York, NY 10029 USA
[2] Mt Sinai Med Ctr, New York, NY 10029 USA
[3] Mt Sinai Sch Med, New York, NY USA
[4] Mt Sinai Med Hosp, New York, NY USA
来源：
CIRCULATION | 2000年 / 102卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3216
引用
收藏
页码：665 / +
页数：2
相关论文
共 50 条
  • [21] Does abciximab limit CK-MB release after rotational atherectomy of type B2 lesions?: Results of the RotaReoPro randomized trial.
    Reich, D
    Kini, A
    Brown, E
    King, T
    Sharma, SK
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (6A): : 35P - 35P
  • [22] QUANTITATION OF CK-MB RELEASE - DIAGNOSTIC UTILITY IN CORONARY-ARTERY BYPASS-GRAFTING
    DEVINE, JE
    WIENS, RD
    HALSTEAD, JM
    CODD, JE
    CLINICA CHIMICA ACTA, 1986, 156 (02) : 145 - 149
  • [23] Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention
    Kereiakes, DJ
    Broderick, TM
    Roth, EM
    Whang, D
    Shimshak, T
    Runyon, JP
    Hattemer, C
    Schneider, J
    Lacock, P
    Mueller, M
    Abbottsmith, CW
    AMERICAN JOURNAL OF CARDIOLOGY, 1999, 84 (04): : 391 - 395
  • [24] Clinical impact of troponin and CK-MB release after percutaneous coronary intervention with rotational atherectomy; results from a prospective large registry
    Tanner, R.
    Koshy, A.
    Sartori, S.
    Dhulipala, V
    Vinayak, M.
    Feng, Y.
    Mehran, R.
    Kini, A.
    Sharma, S. K.
    HEART, 2023, 109 (SUPPL_6) : A47 - A48
  • [25] Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction
    Raveendran, Ganesh
    Ting, Henry H.
    Best, Patricia J.
    Holmes, David R., Jr.
    Lennon, Ryan J.
    Singh, Mandeep
    Bell, Malcolm R.
    Long, Kirsten Hall
    Rihal, Charanjit S.
    MAYO CLINIC PROCEEDINGS, 2007, 82 (02) : 196 - 202
  • [26] Long-Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention
    Koutouzis, Michael
    Lagerqvist, Bo
    Oldgren, Jonas
    Akerblom, Axel
    Wahlin, Magnus
    Karlsson, Thomas
    Albertsson, Per
    Matejka, Goran
    Grip, Lars
    CLINICAL CARDIOLOGY, 2010, 33 (11) : 686 - 692
  • [27] Comparison by Meta-Analysis of Eptifibatide and Tirofiban to Abciximab in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
    Ottani, Filippo
    La Vecchia, Luigi
    De Vita, Maria
    Catapano, Ottorino
    Tarantino, Fabio
    Galvani, Marcello
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 106 (02): : 167 - 174
  • [28] Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy)
    Kirtane, Ajay J.
    Parise, Helen
    Mehran, Roxana
    Moses, Jeffrey W.
    Fahy, Martin
    Bertrand, Michel E.
    Ohman, E. Magnus
    White, Harvey D.
    Feit, Frederick
    Colombo, Antonio
    McLaurin, Brent T.
    Cox, David A.
    Ware, James H.
    Pocock, Stuart J.
    Lansky, Alexandra J.
    Stone, Gregg W.
    AMERICAN JOURNAL OF CARDIOLOGY, 2010, 106 (02): : 180 - 186
  • [29] The prognostic value of CK-MB elevation after percutaneous coronary intervention in patients with chronic renal insufficiency
    Gruberg, L
    Ahmed, JM
    Suddath, WO
    Hongsheng, W
    Jaffi, MR
    McCarthy, NE
    Adamian, M
    Cioara, C
    Laird, JR
    CIRCULATION, 2000, 102 (18) : 390 - 390
  • [30] Use of tirofiban or abciximab during percutaneous coronary intervention in post-MI patients: is there any differences?
    Assali, A
    Moustapha, A
    Sdringola, S
    Ghani, M
    Salloum, J
    Saikia, S
    Schroth, G
    Rosales, O
    Anderson, HV
    Smalling, RW
    EUROPEAN HEART JOURNAL, 2001, 22 : 663 - +
12345